COMBINATION THERAPY USING LIPOSOMAL IRINOTECAN AND PARP INHIBITOR FOR THE TREATMENT OF CANCER Russian patent published in 2021 - IPC A61K9/127 A61K31/04 A61K31/166 A61K31/4184 A61K31/436 A61K31/4745 A61K31/502 A61K31/55 A61P35/00 

FIELD: medicine; oncology.

SUBSTANCE: group of inventions relates to the field of medicine, namely to oncology; it is intended for the treatment of a patient with solid tumor. A method for the treatment of a patient with solid tumor includes i) systematic injection to a patient of liposomal irinotecan once every two weeks and ii) injection of poly(ADP-ribose)polymerase (hereinafter – PARP) inhibitor daily during from 3 to 10 days between sequential injections of liposomal irinotecan. PARP inhibitor is injected beginning after at least 2, 3, 4 or 5 days after the injection of liposomal irinotecan and ending at least before 1, 2, 3, 4 or 5 days till the next injection of liposomal irinotecan. In another option, a method for the treatment of a patient with solid tumor includes introduction to a patient of an antineoplastic therapy in 28-day treatment cycle. The antineoplastic therapy consists of: i) injection of liposomal irinotecan on 1 and 15 day of the treatment cycle and ii) injection of poly(ADP-ribose)polymerase (PARP) inhibitor during one or more days beginning at least after 3 days after the injection of liposomal irinotecan and ending at least before 1 day till the injection of additional liposomal irinotecan. In on more option, a method for the treatment of a patient with cancer and with tumor includes i) parenteral injection to a patient of effective amount of liposomal irinotecan and ii) injection to a patient of effective amount of poly(ADP-ribose)polymerase (PARP) inhibitor, where PARP inhibitor is injected to a patient after an effective interval for irinotecan removal from plasma. The effective interval for irinotecan removal from plasma is: a) from about 48 to about 120 hours and/or b) 2, 3, 4 or 5 fays.

EFFECT: use of the group of inventions allows increasing the efficiency of the treatment of cancer in a patient.

28 cl, 21 dwg, 16 tbl, 10 ex